405 related articles for article (PubMed ID: 20510487)
1. [TNFα blocking agents and sarcoidosis: an update].
Toussirot E; Pertuiset E
Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
Baughman RP; Iannuzzi M
BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R; Bansback N; Brennan A
Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
Ortonne JP
Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346
[No Abstract] [Full Text] [Related]
6. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
Régent A; Mouthon L
Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
[TBL] [Abstract][Full Text] [Related]
7. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
8. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
Lapadula G
Reumatismo; 2005; 57(4 Suppl):22-9. PubMed ID: 16385352
[TBL] [Abstract][Full Text] [Related]
9. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
Denys BG; Bogaerts Y; Coenegrachts KL; De Vriese AS
Clin Sci (Lond); 2007 Mar; 112(5):281-9. PubMed ID: 17261090
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soto MJ;
Medicine (Baltimore); 2008 Nov; 87(6):345-364. PubMed ID: 19011506
[TBL] [Abstract][Full Text] [Related]
11. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
12. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
Toussirot E; Pertuiset E; Kantelip B; Wendling D
Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
17. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
18. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
Massara A; Cavazzini L; La Corte R; Trotta F
Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman RP; Lower EE; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
